Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00657709 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3630

Enrollment

INDUSTRY

Sponsor class

Conditions

Serogroup B Meningococcal Meningitis

Interventions

BIOLOGICAL: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)
BIOLOGICAL: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)
BIOLOGICAL: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)
BIOLOGICAL: Infanrix Hexa
BIOLOGICAL: Menjugate
BIOLOGICAL: Prevenar

Sponsor

Novartis Vaccines

Collaborators

[object Object]